期刊文献+

国产加替沙星胶囊剂人体药动学及生物等效性研究 被引量:15

Studies on the pharmacokinetics and bioequivalence of domestic gatifloxacin capsules in healthy volunteers
下载PDF
导出
摘要 目的 评价加替沙星国产胶囊剂和进口片剂在人体内是否生物等效。方法 采用高效液相色谱紫外检测法测定 2 0名健康受试者单剂量po 40 0mg加替沙星国产胶囊或进口片剂后 ,血浆中加替沙星的浓度。 结果 国产加替沙星胶囊剂和进口片剂的AUC0~ 36 均值分别为 (31 .60± 5 .45)和 (30 .37± 5 .74) μg·h·mL- 1 ,实测cmax均值分别为 (3 .32± 0 .55)和 (3 .37±0 .50 ) μg·mL- 1 ,实测tmax均值分别为 (1 .65± 0 .37)和 (1 .55± 0 .46)h ,国产加替沙星胶囊的相对生物利用度为 (1 0 4 .6±8.6) %。结论 经统计学分析 。 OBJECTIVE: To observe the bioavailability of domestic gatifloxacin capsules and imported tablets. METHOD: A single oral dose of 400 mg domestic capsules or imported tablets were given to 20 healthy volunteers in a randomized crossover study. The concentrations of gatifloxacin were determined by HPLC method. RESULTS: The main pharmacokinetics of the two products were as following: AUC0&middot36(31.60 ± 5.45) and (30.37 ± 5.74) μg &middot h &middot mL-1, cmax(3.32 ± 0.55) and (3.37 ± 0.50) μg &middot mL-1, t max(1.65 ± 0.37) and (1.55 ± 0.46) h, respectively. The relative bioavailability of domestic capsules to imported tablets was (104. 6 ± 8.6)%. CONCLUSION: There were no significant difference between the parameters of the two preparations(P > 0.05). The results demonstrated that the two preparations were bioequivalent.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2003年第6期452-455,共4页 Chinese Pharmaceutical Journal
关键词 加替沙星胶囊剂 人体药动学 生物等效性 研究 Drug products High performance liquid chromatography Organic compounds
  • 相关文献

参考文献5

  • 1杜煜,郭惠元.广谱、高效、低毒的新喹诺酮类抗菌药加替沙星[J].国外医药(抗生素分册),2001,22(1):34-39. 被引量:112
  • 2Christoph KN, Michaela S, Martina K, et al. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers[J]. Antimicrob Agents Chemother, 2001,45 ( 1 ) : 293.
  • 3Silke L, Susanne E, Mago R, et al. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium[J]. Antimicrob Agents Chemother, 1999, 43 (5):1067.
  • 4Mitsuyoshi Nakashima, Toshihiko Uematsu, Kazukiro Kosuge,et al. Single-and multiple-dose pharmavokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans[J]. Antimicrobial Antimicrob Agents Chemother , 1995,39(12) :2635.
  • 5Annette L, Ivonne K, Klaus B, et al. Comparative pharmacokinetics of cipmfloxacin, gatifloxacin, grepafloxaein, levofloxacin,trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers [ J ]. Antimicrob Agents Chemother , 2000, 44(10):2600.

二级参考文献32

  • 1副岛林造.Gatifloxacin(GFLX)の概要[J].日本化学疗法学会杂志,1999,47(2):1-1.
  • 2柴孝也.健康成人におけゐgatifloxacinの体内动态に及ほす水酸化ろルミニウム及びシメジンの影响[J].日本化学疗法学会杂志,1999,47(S-2):218.
  • 3柴孝也.健康成人におけゐgatifloxacinの体内动态に及ぼす铁剂の并用,びに绿茶またば牛乳によゐ服药の影响[J].日本化学疗法学会杂志,1999,47(S-2):224.
  • 4(文)藤笃,中山一朗,大道光秀,他.内科领域感染症に对すゐgatifloxacin の前期第Ⅱ相临床试验[J].日本化学疗法学会杂志,1999,47(S-2):260.
  • 5(文)藤笃,大道光秀,荒川正昭,他.呼吸器感染症に对すゐgatifloxacinの后期第Ⅱ相临床试验[J].日本化学疗法学会杂志,1999,47(S-2):277.
  • 6河田幸道,熊本悦明,折笠精一,他.泌尿器科领域感染症に对すゐgatifloxacinの前期第Ⅱ相临床试验[J].日本化学疗法学会杂志,1999,47(S-2):292.
  • 7河田幸道,熊本悦明,折笠精一,他.泌尿器科领域感染症に对すゐgatifloxacin の后期第Ⅱ相临床试验[J].日本化学疗法学会杂志,1999,47(S-2):308.
  • 8由良二郎,岩井重富,中村阳一,他.外科领域におけゐgatifloxacinの基础的,临床的检讨[J].日本化学疗法学会杂志,1999,47(S-2):323.
  • 9荒田次郎,神崎宽子,石桥康正,他.皮肤科领域におけゐgatifloxacinの基础的,临床的检讨[J].日本化学疗法学会杂志,1999,47(S-2):338.
  • 10松田静治,千村哲朗,平山寿雄,他.产妇人科领域におけゐgatifloxacinの基础的,临床的检讨[J].日本化学疗法学会杂志,1999,47(S-2):351.

共引文献111

同被引文献59

引证文献15

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部